NEO - ネオス・ファ―マシュ―ティカルズ （NeoGenomics Inc.）NEOのニュース
NeoGenomics Inc. (NEO) did well last session? 2023/03/07 16:40:00 US Post News
In Monday’s session, NeoGenomics Inc. (NASDAQ:NEO) marked $17.51 per share, down from $17.99 in the previous session. While NeoGenomics Inc. has underperformed by -2.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO fell by -13.83%, with highs and lows ranging from $20.78 to $6.00, whereas […]
Neogenomics: At A Key Inflection Point In Growth Route (NASDAQ:NEO) 2023/03/03 08:55:59 Seeking Alpha
NeoGenomics'' profitability and return on capital are a concern, so FY23 will be the key year to evidence the success of the new strategy. Find out why NEO stock is a Hold.
NeoGenomics upgraded to buy at Benchmark on performance improvement program (NASDAQ:NEO) 2023/02/24 15:57:43 Seeking Alpha
Benchmark has upgraded NeoGenomics (NEO) to buy from hold noting that a management performance improvement program is poised to deliver profitability.
NeoGenomics, Inc. - Consensus Indicates Potential 17.6% Upside - DirectorsTalk Interviews 2023/02/24 11:16:11 DirectorsTalk
NeoGenomics, Inc. - Consensus Indicates Potential 17.6% Upside
Here’s Why NeoGenomics’ (NASDAQ:NEO) Q4 Results Thrilled Investors 2023/02/24 07:11:55 TipRanks
Shares of NeoGenomics (NASDAQ:NEO) soared more than 24% on Thursday despite reporting mixed fourth-quarter results. The rally reflected investors’ …
NeoGenomics, Inc. (NEO) Class Action Alert: Robbins LLP Encourages Investors with Significant Losses in NeoGenomics, Inc. to Contact the Firm 2022/12/30 20:52:00 GlobeNewswire
SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- The Class : Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, for violations of the Securities Exchange Act of 1934. NeoGenomics provides cancer tests and testing services to doctors, clinics, hospitals, and pharmaceutical companies. Among the Company’s portfolio of tests are next generation sequencing (“NGS”) tests.
Results from NeoGenomics Inc. (NEO) show risk 2022/12/29 15:40:00 US Post News
The share price of NeoGenomics Inc. (NASDAQ:NEO) fell to $8.92 per share on Wednesday from $9.09. While NeoGenomics Inc. has underperformed by -1.87%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO fell by -72.61%, with highs and lows ranging from $35.34 to $6.00, whereas the […]
Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial 2022/12/22 21:15:00 Kwhen Finance
NeoGenomics Inc. (NEO) can beat the pack with these strategies 2022/12/22 12:00:00 US Post News
As of Wednesday, NeoGenomics Inc.’s (NASDAQ:NEO) stock closed at $9.69, down from $10.44 the previous day. While NeoGenomics Inc. has underperformed by -7.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO fell by -72.16%, with highs and lows ranging from $35.40 to $6.00, whereas the […]
NEO INVESTOR ALERT: First And Only NeoGenomics Class Action Filed by Gibbs Law Group 2022/12/22 01:48:00 Wallstreet:Online
Gibbs Law Group reminds investors it has filed the first and only class action lawsuit against NeoGenomics, Inc. (NASDAQ: NEO) and certain of its officers and directors on behalf of investors who purchased NeoGenomics securities from February 27, 2020 through April 26, 2022, inclusive. Since the lawsuit was filed, NeoGenomics subsidiary Inivata was also sued on December 21, 2022 for alleged patent
Is NeoGenomics Inc. (NASDAQ:NEO) A Better Buy Than Others After A -83.83% Fall In This Year? 2022/10/15 13:00:00 Marketing Sentinel
In last trading session, NeoGenomics Inc. (NASDAQ:NEO) saw 0.7 million shares changing hands with its beta currently measuring 0.98. Company’s recent per share price level of $7.05 trading at -$0.52 or -6.87% at ring of the bell on the day assigns it a market valuation of $972.90M. That closing price of NEO’s stock is at … Is NeoGenomics Inc. (NASDAQ:NEO) A Better Buy Than Others After A -83.83% Fall In This Year? Read More »
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022 - Stocks News Feed 2022/10/13 11:43:40 Stocks News Feed
FT. MYERS, FL / ACCESSWIRE / October 13, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its third quarter 2022, financial results on Tuesday, November 8, 2022. The Company has scheduled a webcast and conference call to discuss their… Read More »NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
NeoGenomics, Inc.: NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022 2022/10/13 11:08:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / October 13, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it p…
Investing in NeoGenomics Inc. (NEO) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/10/12 14:24:00 US Post News
NeoGenomics Inc. (NASDAQ:NEO) closed Tuesday at $7.50 per share, down from $7.64 a day earlier. While NeoGenomics Inc. has underperformed by -1.83%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO fell by -81.74%, with highs and lows ranging from $47.13 to $6.85, whereas the simple […]
How did NeoGenomics Inc. (NEO) fare last session? 2022/10/05 13:00:00 US Post News
A share of NeoGenomics Inc. (NASDAQ:NEO) closed at $9.25 per share on Tuesday, up from $8.71 day before. While NeoGenomics Inc. has overperformed by 6.20%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO fell by -78.60%, with highs and lows ranging from $47.67 to $6.85, […]